Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Virchows Archiv : an International Journal of Pathology
|
June 27, 2025
Low heterogeneity of tumor grades in multiple MRI-targeted prostate biopsies argues for the aggregate method of grading
Oliver Hommerding, Fereschte Sara Rejai, Anna Scherping, et al.
Nuklearmedizin. Nuclear Medicine
|
December 1, 2025
Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors
Barbara Kreppel, Jana Fink, Christine Sanders, et al.
Oncotarget
|
April 16, 2016
MERTK as a novel therapeutic target in head and neck cancer
Anne von Mässenhausen, Christine Sanders, Britta Thewes, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
July 1, 2024
Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
Marit Bernhardt, Leonie Weinhold, Christine Sanders, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2024
Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection
Thomas Zeyen, Lea L Friker, Daniel Paech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2016
Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Johannes Brägelmann, Niklas Klümper, Anne Offermann, et al.
Molecular Cancer Therapeutics
|
July 9, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Racha Hosni, Niklas Klümper, Christine Sanders, et al.
Molecular Cancer Therapeutics
|
June 13, 2025
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma
Racha Hosni, Niklas Klümper, Christine Sanders, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Virchows Archiv : an International Journal of Pathology
|
June 27, 2025
Low heterogeneity of tumor grades in multiple MRI-targeted prostate biopsies argues for the aggregate method of grading
Oliver Hommerding, Fereschte Sara Rejai, Anna Scherping, et al.
Nuklearmedizin. Nuclear Medicine
|
December 1, 2025
Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors
Barbara Kreppel, Jana Fink, Christine Sanders, et al.
Oncotarget
|
April 16, 2016
MERTK as a novel therapeutic target in head and neck cancer
Anne von Mässenhausen, Christine Sanders, Britta Thewes, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
July 1, 2024
Peer-to-peer validation of Ki-67 scoring in a pathology quality circle as a tool to assess interobserver variability: are we better than we thought?
Marit Bernhardt, Leonie Weinhold, Christine Sanders, et al.
Journal of Cancer Research and Clinical Oncology
|
September 28, 2024
Transient MRI changes and neurological deterioration in glioblastoma upon SARS-CoV-2 infection
Thomas Zeyen, Lea L Friker, Daniel Paech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2016
Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Johannes Brägelmann, Niklas Klümper, Anne Offermann, et al.
Molecular Cancer Therapeutics
|
July 9, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Racha Hosni, Niklas Klümper, Christine Sanders, et al.
Molecular Cancer Therapeutics
|
June 13, 2025
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma
Racha Hosni, Niklas Klümper, Christine Sanders, et al.
Page
of 2